// App-Quantinova.ai

2560 : A Highly Selective Anti-ROR1 Monoclonal Antibody Inhibits Human Acute Myeloid Leukemia CD34+ Cell Survival and Self-Renewal.

Researchers

Presenter

  • Anil Sadarangani

Principal Investigators

  • George F. Widhopf II

  • Thomas J. Kipps

  • Rui-kun Zhong

  • Charles Prussak

  • Marco A. Marra

  • John E Dick

  • Mark D. Minden

  • Edward D. Ball

  • Dennis A. Carson

  • Catriona Jamieson

Medical Centers

  • Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada

  • Division of Medical Oncology, Princess Margaret Hospital/University of Toronto, Toronto, ON, Canada

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Division of Cell and Molecular Biology, University Health Network, Toronto, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Acute myelocytic leukemia

  • B cell lymphomas

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 34

Drug/Treatment

  • Mitomycin-C

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved